Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
CAR T-cell therapy is a promising treatment for patients with multiple myeloma, whose disease has relapsed or is not responding to (refractory) prior treatments. It is a highly-specialized therapy that involves genetically modifying a patient's own T
cells to attack their multiple myeloma using a target called B-cell maturation antigen (BCMA). The FDA has approved CAR T-cell therapy for multiple myeloma. Dana-Farber Brigham Cancer Center is a leader in bringing new CAR T-cell therapies to patients
in need and led the clinical trial that led to FDA approval of CAR T for multiple myeloma.
CAR T-cell therapy is approved for multiple myeloma that has relapsed after or is refractory to at least four prior treatments. The clinical trial showed the CAR T-cell therapy to be highly effective for patients whose disease had relapsed after or not
responded to multiple prior treatments.
Patients are evaluated carefully to determine if this therapy is appropriate for them. As a new product, there may be limited availability of CAR T-cell therapy for multiple myeloma. Your physician will discuss this with you and whether a clinical trial
of another CAR T-cell product may be an option. Learn more about CAR T-cell therapy.
Dana-Farber Brigham Cancer Center also offers clinical trials of other CAR T-cell therapies for multiple myeloma.
Patients who meet the following criteria may be appropriate for CAR T-cell therapy:
Patients must have a referral from their oncologist to Dana-Farber Brigham Cancer Center's Jerome Lipper Multiple Myeloma Center to be evaluated for CAR T-cell therapy.
As a new product, there may be limited availability of CAR T-cell therapy for multiple myeloma. Your physician will discuss this with you and whether a clinical trial of another CAR T-cell product may be an option.
Grandmother Living Active Life after CAR-T TreatmentThe FDA recently approved the first CAR T-cell therapy for multiple myeloma. Nikhil Munshi, MD, and clinical trial participant, Susan Voigt share what this significant advance means for patients.
Contact Information for CAR T-Cell Therapy
For more information about CAR T-cell therapy, please call 877-801-CART (2278).